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Abstract 
Apatitic bone cements have been used as a clinical bone substitutes and drug delivery 
vehicles for therapeutic agents in orthopedic applications. This has led to their 
combination with different drugs with known ability to foster bone formation. Recent 
studies have evaluated Simvastatin for its role in enhanced bone regeneration, but its 
lipophilicity hampers incorporation and release to and from the bone graft. 
In this study, injectable calcium phosphate foams (i-CPF) based on α-tricalcium 
phosphate were loaded for the first time with Pitavastatin. The stability of the drug in 
different conditions relevant to this study, the effect of the drug on the i-CPFs properties, 
the release profile, and the in vitro biological performance with regards to mineralization 
and vascularization were investigated. Pitavastatin did not cause any changes in neither 
the micro nor the macro structure of the i-CPFs, which retained their biomimetic 
features.  PITA-loaded i-CPFs showed a dose-dependent drug release, with early stage 
release kinetics clearly affected by the evolving microstructure due to the setting of 
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cement. In vitro studies showed dose-dependent enhancement of mineralization and 
vascularization. Our findings contribute towards the design of controlled release with 
low drug dosing bone grafts: i-CPFs loaded with PITA as osteogenic and angiogenic 
agent. 
 
Keywords:   Controlled Drug Release; Vascularization; Mineralization; Rat 
Mesenchymal Stem Cells; Endothelial Progenitor Cells. 
 
1. Introduction 
Bone defects represent a major health burden, especially when they are of critical size 
and cannot heal following the usual regeneration mechanisms of bone [1]. In such cases 
bone grafting surgery is required, and in this context synthetic bone biomaterials have 
an increasing demand. Among the different biomaterials available, calcium phosphate 
cements (CPC) present several advantages that have fostered their study and application 
[2–4]. In particular, their composition mimicking the bone mineral phase, their ability 
to strongly bond with bone, their injectability and self-setting ability are some of their 
main assets [5–9]. Moreover, their intrinsic micro-nanoporosity makes them ideal 
candidates as drug delivery vehicles [10, 11], and have thus been studied in combination 
with different drugs including anti-inflammatories, antibiotics or anti-osteoporotic drugs 
[12–15]. 
Interconnected macroporosity is a key feature of synthetic bone grafts, since it allows 
circulation of nutrients and cell infiltration and enhances resorption and bone ingrowth. 
Moreover, when injectable CPCs are used as matrices for the delivery of drugs or active 
molecules, the presence of interconnected macropores has been shown to significantly 
enhance drug delivery [14]. So far, a number of methods have been investigated to obtain 
macroporous CPCs [16–21]. In this work we focus specifically on injectable calcium 
phosphate foams (i-CPF) obtained by foaming biocompatible surfactants. This method 
has been found adequate for obtaining stable scaffolds with interconnected 
macroporosity [17]. 
Statins are extensively used drugs, employed mainly as inhibitors for the cholesterol 
biosynthesis. Additionally, they are known to present several pleotropic effects, such as 
improving endothelial function, decreasing oxidative stress and inflammation, or 
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inhibiting the thrombogenic response, among others [22].  Interestingly, Mundy et al.  
reported that they also played a role in bone formation, through the stimulation of Bone 
Morphogenetic Protein-2 (BMP-2) expression [23]. This led to a wide investigation, 
focusing especially on simvastatin (SIM), as a potential drug for bone regeneration [23, 
24]. However, the hydrophobic nature of SIM results into low oral bioavailability (≤5%), 
due to extensive first-pass metabolism in the gastro-intestinal wall and high extraction 
in the liver [25]. The hydrophobic nature of SIM also hampers its uniform incorporation 
in water-based matrices, as is the case of CPCs, which are formed by a combination of 
powder and aqueous liquid phase. 
With the aim of fostering bioavailability and ease of incorporation in CPCs, a more 
hydrophilic statin, Pitavastatin (PITA) in combination with a macroporous CPC has been 
investigated for the first time in this work. Due to its higher oral absorption and oral 
bioavailability, PITA has a higher potency than SIM [26–28]. Additionally, its higher 
solubility provides a better platform for uniform incorporation to CPFs through the 
aqueous liquid phase. Moreover, although the studies on the pleiotropic effects of PITA 
are scarce [29], some findings suggest that it enhances bone turnover markers [30]; and 
gene expressions for mineralization [31]. 
The aim of this study is to explore the feasibility of incorporating PITA in i-CPFs as 
a strategy to foster the bone regenerative process at the defect site, using a lower dosage 
than SIM due to its higher potency. To this end, the effects of PITA on mesenchymal 
stem cells and on endothelial progenitor cells were evaluated, and the interactions of 
PITA with the physic-chemical properties of i-CPFs were assessed, together with its drug 
release properties from i-CPFs. 
 
2. Materials and methods 
 
2.1. Pitavastatin stability 
Pitavastatin Calcium (C25H23FNO4 * 0.5Ca * 2H2O; Tocris Bioscience, UK) is a very 
slightly soluble compound in water, which was received in powder form and incorporated 
in the liquid phase. The molecular structure of PITA is shown in Fig. 1. In the evaluation 
of the stability of PITA, two main factors were taken into account: pH and temperature. The 
temperature stability was evaluated with solutions of PITA prepared in Phosphate Buffer 
Saline (PBS) at different concentrations (5, 50 and 100 µM) and stored at 5 ºC and 37 
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ºC with a  pH  o f  6 .5 .  Similarly, PITA’s stability was assessed at alkaline pH based on 
the fluctuations registered during cement setting; During the setting reaction of i-CPF the 
pH reaches alkaline values of pH 9.5 and eventually shifts to neutral pH 7 during the initial 
24 h [32]. PITA was dissolved in water (5, 25, 50, 75 and 100 µM) and stored at 37 ºC. 
For the pH stability studies water was adjusted to pH 8 and pH 9.5 by addition of 0.01 M 
NaOH and PITA solutions were subsequently prepared. The quantification of PITA 
solutions at various time points was carried out with High performance liquid 
chromatography (HPLC) in a Shimadzu HPLC system. A mobile phase of Acetonitrile:  
0.1% phosphoric acid at a ratio of 50:50 (v/v), at a flow rate of 0.5 ml/min was passed 
through a C8 column (Shim-pack, Shimadzu). An injection volume of 10 µL of the release 
sample was measured by photodiode array (PDA) at λmax = 245 nm. 3 replicates were 
analyzed for each condition. 
 
2.2. Evaluation of the effects of Pitavastatin on mesenchymal stem cells and 
endothelial progenitor cells in vitro 
The osteogenic and angiogenic effects of PITA were evaluated in vitro with rat 
Mesenchymal stem cells (rMSCs) and endothelial progenitor cells (EPCs) respectively. 
Both cell types were extracted from femurs of young Lewis rats at the Institute for 
Bioengineering of Catalonia (IBEC), as in previous works [33]. Cell phenotypes were 
previously characterized by flow cytometry [34]. rMSCs cells were expanded in Advanced 
DMEM supplemented with 10% fetal bovine serum (FBS), 20 mM HEPES buffer 
solution, penicillin/streptomycin antibiotics (50 U/ml and 50 µg/ml, respectively), and 2 
mM L-glutamine (all from Invitrogen) at 37 ºC with 5% CO2 and 95% relative humidity. 
On the other hand, supernatant containing EPCs were centrifuged and re-suspended in 
EBM medium (Lonza) supplemented with EGM-2 BulletKit and 5% FBS. Both cell types 
were used from passage 4 for all the experiments. 104 cells/well were seeded in 24 well 
plates and cultured in their corresponding medium with PITA (0.1, 1 and 10 µΜ) and 
Tissue culture polystyrene (TCPS) was used as control.  PITA was received in powder 
form and used as received to prepare a stock solution in MilliQ water, which was further 
diluted to the final concentration of 0.1, 1 and 10 µM in cell culture medium. 
The expression of osteogenic marker genes in rMSCs (BMP-2, Osteocalcin, Collagen-I) and 
vascularization genes in rEPCs (VEGFA, VEGFR-1, VEGFR-2) was determined through RT-
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qPCR assay at various time points (6 and 24h, 3 and 7 days). The DNA primer sequences are 
detailed in Table 1. A detailed protocol and calculations have been described elsewhere [35]. 
Briefly, at each culture time, total RNA was extracted using RNeasy®Mini Kit (Qiagen, Hilden, 
Germany) and quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Montchanin, DE, USA). RNA (200 ng) was retrotranscribed to cDNA using the 
QuantiTect Reverse Transcription Kit (Qiagen) and retrotranscribed to cDNA using the 
QuantiTect SYBR Green RT-PCR Kit (Qiagen) in a StepOnePlus Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). The fold change for each gene expression was 
obtained after normalizing the values to TCPS at 6h and to β-actin. 
2.3. Preparation of Pitavastatin loaded injectable calcium phosphate foams 
α-TCP was used as a solid phase of i-CPFs and was obtained as described elsewhere [14].  
2 wt.% of precipitated hydroxyapatite (HA; BP-E341, Merck, Germany) was added as 
a seed in the powder. 10 wt% Pluronic F-127 (Sigma Aldrich, USA) was blended with 
the solid phase for the preparation of the i-CPFs. The liquid phase was a solution of 1 
wt% of Polysorbate 80, herein Tween80 (Polysorbate 80, Sigma Aldrich, USA) in 
distilled water. PITA solutions were prepared at 50, 75, 100 and 200 µM by incorporating 
it in the liquid phase. 
Self-setting i-CPFs were foamed by mixing the solid and the liquid phase at a liquid-to-
powder ratio of 0.55 at 7000 rpm for 30 s using a domestic hand mixer. The foams were 
injected in Teflon cylindrical moulds of 6 mm x 12 mm and left to consolidate in 100 % 
relative humidity at 37 ºC, followed by immersion in water at 37ºC for 7 days to allow for 
complete reaction, prior to physic-chemical characterization. 
 
2.4. Physico-chemical characterization of i-CPFs 
The microstructure of a fracture region of the i-CPFs was characterized by field emission 
scanning electron microscopy (FESEM) (Neon 40, Zeiss, Germany) at 10 kV working 
voltage. Prior to observation, samples were Au-sputter coated (K950X, Emitech, US). 
The Specific Surface Area (SSA) of i-CPFs was measured by Nitrogen adsorption in an 
ASAP 2020 (Micromeritics) with 6 cylindrical samples, using the Brunauer-Emmet-
Teller (BET) method. 
Helium pycnometry (AccuPyc 1330, Micromeritics, USA) was used to measure the 
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skeletal density of i-CPFs and i-CPFs with 100 µM PITA with four cylindrical samples. 
Mercury intrusion porosimetry (MIP, AutoPore IV, Micrometrics, USA) was performed 
to determine the pore entrance size distribution (PESD) within the materials. Four 
cylindrical samples were introduced in the sample holder for the measurement, and a 
single measurement was performed for each composition.  
 
2.5. Micro-computed tomography 
A 3-dimensional micro-computed (3D micro-CT) system TOMOLIBRIR developed at 
the FRAUNHOFER IZFP Saarbrucken, Germany was used to evaluate the three-
dimensional (3-D) morphology of CPFs. The scanner was operated to obtain a voxel size 
of 43 µm3, at 100 kV and 9 W X-ray power with a data acquisition and reconstruction 
software, Volex. The samples employed were cylinders with 6 mm in diameter and 12 
mm height. The 3-D volume was then reconstructed using the software Amira network 
(version 5.4.3). 
2.6. Evaluation of Pitavastatin release 
For drug release studies, i-CPFs were prepared with the liquid phase containing PITA at 
different concentrations (50, 75, 100 and 200 µM) as described in Section 2.3. They were 
injected in 2 mm x 6 mm Teflon molds adapted from the United States Pharmacopoeia 
(USP) ointment cell with only one open side allowing contact with the release medium. 
Prior to release, they were kept for 5 h in 100% relative humidity to have sufficient 
cohesion. The total amount of PITA loaded per sample was calculated from equation 1 by 
weighing each i-CPF (𝑊𝑊𝑖𝑖−𝐶𝐶𝐶𝐶𝐶𝐶𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇) before release and employing the concentration of PITA 
in the liquid phase, as well as the  weight (W) of solid phase and liquid phase 





𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 +𝑊𝑊𝑆𝑆𝑆𝑆𝑆𝑆𝐿𝐿𝐿𝐿 𝑝𝑝ℎ𝑎𝑎𝑎𝑎𝑎𝑎+𝑊𝑊𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 𝑝𝑝ℎ𝑎𝑎𝑎𝑎𝑎𝑎
× 𝑊𝑊𝑖𝑖−𝐶𝐶𝐶𝐶𝐶𝐶𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇                           (1) 
Release studies were then conducted for 6 days by immersing the i-CPFs moulds in 5 mL 
of Phosphate Buffer Saline (PBS, pH=7.4) at 37ºC with continuous stirring of 100 rpm. 
At each time point 350 µL of release medium was withdrawn and replaced with 350 µL 
of fresh PBS. The amount of drug released was quantified by measuring the concentration 
of PITA in the release media collected at each time point with HPLC following the 
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protocol described in the previous section. The cumulative release was plotted as a 
function of time after correcting the data for evaporation of PBS during 6 days. 
Additionally, the data for total percentage of PITA released was corrected for degradation 
occurred during setting. Modelling was performed using the Korsmeyer-Peppas (KP) 
model. The variable fitted is the quantity released at time t (Mt), normalized by the 
maximum quantity released M∞ (Eq. (2)): 
Mt  =  M∞. k. tn       (2) 
where k is a constant that accounts for structural parameters of the material and 
characteristics of the active principle such as the effective coefficient of diffusion. The 
exponent n allows the identification of the mechanism controlling the release. 
Specifically, for a given geometry of the sample it allows discerning between a release 
controlled by Fickian diffusion, swelling/case II transport or an Intermediate situation.  
The KP model is applicable only up to 60% of the quantity released. The exponent n 
describes the shape of the curve. The quantity released as a function of time was thus fitted 
with the KP equation, and both the value of the exponent n and the correlation coefficient 
R2 were reported. 
 
2.7. Statistics 
Statistical differences were determined using one-way ANOVA with Tukey’s post hoc 
tests using minitab software. Statistical significance was considered when P < 0.05. Data 
are presented as mean ± standard deviation. 
3. Results 
3.1. Stability of PITA 
Assessment of the stability of PITA at different temperatures is relevant in views of storage 
(5ºC) and drug release experiments (37ºC), while pH stability is important with views on its 
incorporation to CPCs. This is reported in Figure 2 up to 9 days. It was found that PITA 
in PBS was stable at both 5 and 37 ºC (Fig. 2, top), as no degradation was detected (P 
>0.05), allowing to perform the drug release assays at 37ºC without risk of degradation 
of PITA, and if required, samples could be stored in the fridge. In contrast, it was observed 
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that PITA was degraded at basic pH (Fig. 2, bottom), particularly at high concentrations 
of 50, 75 and 100 µM. The degradation was found to be similar at pH 8 or 9.5, and the 
amount degraded in the solutions corresponds to ~8% in the first 24 h calculated with 
equation (3). The estimated degradation of PITA during i-CPF setting according to the 
setting pH of CPCs determined in previous works [32] was calculated with the following 

















h          (3) 
The degradation of PITA at pH 8 and pH 9.5 has been calculated as a function of time for 
the initial 24 h (Table 2). 
 
3.2. Effects of Pitavastatin on mesenchymal stem cells and endothelial progenitor cells 
in vitro 
The potential effects of PITA on the expression of some genes involved in bone 
regeneration were evaluated through RT-qPCR studies. The relative fold change in the 
expression by rMSCs of some osteogenic marker genes, namely Osteocalcin (OCN), 
collagen type 1 (Col type 1) and Bone Morphogenetic Protein-2 (BMP-2) is shown in 
Fig. 3, left column. An overexpression of OCN was observed in presence of PITA at 72h, 
which was more marked for the 0.1 µM dose. This concentration led also to an 
overexpression of OCN at early time points (6 and 24h) and to a significant increase in 
both Col type 1 gene expression at 72h compared to control, whereas no significant effect 
was observed for 1 µM PITA. On the other hand, BMP-2 gene expression was observed 
to decrease with progressing time yet it was significantly higher for both 0.1 µM and 1 
µM PITA compared to the control at 72 h. 
Concerning EPCs, the gene expression of VEGFA, VEGF-R1, and VEGF-R2 were studied 
as an indication of the effect of PITA on vascularization, and the results are shown in the 
right column of Fig. 3. For the initial hours of 6, 24 and 48 h, in general PITA showed 
lower expression for vascularization factors than the control. Then, 0.1µM PITA induced 
an overexpression of VEGF-R1, VEGF-R2 and VEGFA at 72h compared to control. In 
contrast, PITA at 1 µM produced a very significant decrease on the expression of the 
three genes (VEGFA, VEGF-R1 and VEGF-R2) at 72h. 
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3.3. Synthesis and characterization of PITA loaded i-CPFs 
PITA loaded i-CPFs were synthesized and their physic-chemical properties were evaluated 
as shown in Fig. 4 and Table 3. The  i-CPFs showed level 3 cohesion [36] which remained 
unchanged with the PITA-loading. The characterization of the microstructure was 
conducted with control i-CPF and PITA loaded i-CPF (100 µM), the highest 
concentration evaluated in the stability studies. The microstructure of the materials with 
and without PITA (100 µM) in the bulk of i-CPFs, both displayed similar features. 
Entangled plate-like crystals derived from the dissolution-precipitation of α-TCP 
responsible for cement hardening were observed in the control as well as in the PITA 
loaded i-CPFs. The drug was completely solubilized in the liquid phase and CDHA was 
formed as a result of the hydrolysis of the initial solid phase α-TCP in i-CPFs. The 
reconstruction of the µCT scans allowed visualizing homogeneously distributed and 
interconnected porosity in i-CPFs with or without PITA as shown in Fig. 4 (bottom). 
 
Additionally, specific surface area (SSA), skeletal density and total porosity measured 
through MIP showed no significant differences due to the presence of the drug, as 
reflected in Table 3 and Fig. 5. 
 
3.4. Pitavastatin release 
The evaluation of the PITA release kinetics from i-CPFs was evaluated for different 
concentrations of drug added to the liquid phase of i-CPFs (50 µM (50-PITA), 75 µM (75- 
PITA), 100 µM (100-PITA) and 200 µM (200-PITA)) in PBS for 6 days (Fig. 6). The 
cumulative release of PITA showed two different phases. Initially, a burst release was 
recorded in the first 5 h, followed by a slow progressive release up to 72 h, which later 
showed a tendency of stabilization. The release amount shows a dose dependent behavior 
from the initial time points as shown in the amplified image (Fig. 6 b), which is kept until 
the final amount released (Fig. 6 c). 
200-PITA was the i-CPF showing the highest amount of PITA released (Fig. 6 a) which 
accounted only for 40.9 ± 9.1% of the PITA loaded in the sample. Fitting parameters to the 




Many studies have reported the benefits of statins, especially SIM, on bone formation 
as well as on the inhibition of bone resorption [23, 27, 29, 37, 38]. Within the family of 
statins, PITA presents some interesting properties, in particular its lower price, 
hydrophilic properties and its comparable efficiency compared to other statins (i.e. SIM) 
at much lower concentrations. Therefore, PITA has potential advantages in views of 
fostering bone regeneration in combination with bone substitutes. However, to the best 
of our knowledge, the combination of PITA with bone bioceramics as drug delivery 
vehicles is still unexplored. In this work we addressed some aspects that are relevant for 
this application, namely, the stability of PITA under different conditions, its biological 
effects on MSCs and EPCs in vitro, and the feasibility of incorporating it in i-CPFs, 
including the effect of the molecule on the properties of the calcium phosphate foams 
and the release kinetics of the drug. 
PITA solutions in PBS were stable both at 5 and 37 ºC for 9 days, which is interesting 
with regard to potential storage of samples, and also in views of the experimental 
conditions during cell cultures and release experiments. 
The setting of calcium phosphate foams involves a dissolution-precipitation reaction, 
which entails a pH fluctuation. The dissolution of α-TCP initially increases the pH of 
the liquid medium, up to pH=9.5, slowly decreasing to pH=8 in 24 h [32]. Therefore, 
the initial 24 h of the setting reaction act as an alkaline environment for PITA. To 
evaluate whether this high pH range could affect the stability of PITA, different PITA 
concentrations were exposed to alkaline pH of either 8 or 9.5 (Fig.  2). No degradation 
was found for the 5 and 25 µM PITA solution over 9 days of exposure. In contrast, at 
higher concentrations of 50, 75 and 100 µM, a significant degradation was recorded 
which increased with exposure time at both pHs. This implies that there will be a partial 
degradation of PITA due to the pH fluctuations during the setting reactions.  To estimate 
the extent of this degradation, we can assume that, according to previous studies that 
assessed the pH evolution during the setting reaction [32, 39], when PITA is mixed 
with an i-CPF, it will be exposed to a pH ≤ 9.5 for the initial 15h, and to a pH ≤ 8 
during the following 9h. With this in mind, the degradation associated to the pH 
fluctuations during the setting reaction for 24 h was calculated as shown in equation (3), 
yielding 8% of degradation. This value was used for the correction of the final 
percentage of PITA released from the i-CPFs. 
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Statins are described to promote in vitro angiogenesis and osteogenesis in a dose 
dependent manner [31, 40–43]. However, few studies have been conducted with PITA 
to demonstrate such effects. The present work was originally designed for three different 
concentrations of 0.1, 1 and 10 µM. It was found that 10 µM resulted in toxic effects on 
the cell culture with complete loss of cell viability in rMSCs and EPCs. Therefore, the 
study was continued with concentrations of PITA in the cell culture medium of 0.1 µM 
(0.0475 µg/mL) and 1 µM (0.475 µg/mL) (Fig. 3). The results showed an overexpression 
of genes associated to osteogenesis and vascularization with the lowest dosage of PITA 
(0.1 µM). Our findings of OCN and BMP-2 overexpression are in agreement with other 
studies where the bone anabolic effect of PITA was reported to stimulate OCN by 
inhibition of Rho-associated kinase and BMP-2 in human osteoblasts [31] and collagen 
[30]. The present study observed similar results at 72 h with a concentration of 0.1 µM 
in rMSCs whereas a previous work [31] reported overexpression at 48 h with 1 µM in 
human osteoblasts. This difference can be explained as the concentration may depend on 
the type of cells, as seen earlier in other studies with simvastatin and other statins [44–
47]. Our results indicate that PITA induces mineralization, differentiation and 
osteogenesis in rMSCs. 
In the case of EPCs, gene expression values for VEGF, VEGF-R1 and VEGF-R2 
were followed for their key role in angiogenesis. VEGFA plays an important role as key 
regulator to promote growth of vascular endothelial cells and vessel growth, therefore 
an important marker for angiogenesis [48]. VEGFA binds to two receptors including 
VEGF-R1 and VEGF-R2. It has been seen that role of VEGF-R1 is still not well defined 
as it is known as a ‘decoy’ receptor which regulates VEGFA in a negative fashion by 
interfering with binding between VEGFA and VEGF-R2 [49].  On the other hand, recent 
studies claimed that VEGF-R1 plays a role in recruitment of endothelial progenitors 
[50]. Therefore, role of VEGF-R1 is still under debate. Though, VEGF-R2 plays a key 
role in angiogenesis by enhancing effects of VEGFA by binding with it [51]. In the 
present work, a significant increase was observed in VEGFA, VEGF-R2 and VEGF-R1 
at 72 h suggesting stimulation of vascularization by PITA at 0.1 µM. It is important to 
take into account that the increase in VEGF-R2 was three fold with respect to the control, 
which is really essential for binding with VEGFA and stimulating angiogenesis. 
Similarly, PITA [52] and other statins [41, 53, 54] have been previously described to 
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promote angiogenesis. Collectively, our data suggest that PITA has bone anabolic effects 
on both rMSCs and rEPCs, coping well with other studies, where 0.1 µM was also found 
to be the most effective dose [31, 43]. 
In addition to the bone anabolic effects just discussed, PITA being a hydrophilic 
molecule allows direct dissolution in the aqueous liquid medium used for i-CPFs 
synthesis.  This is an advantage, as other statins such as SIM require an additional step 
to convert it from hydrophobic to hydrophilic by lactone ring opening, if solubility in an 
aqueous phase is desired [55]. In contrast, PITA can be directly incorporated in the 
aqueous phase of the self-setting foams to have a homogenous distribution throughout 
the foam volume, which can facilitate a sustained and a prolonged release.  Drug 
incorporation in self-setting cements and foams can often result in the modification of 
the setting times or alteration of the texture or porosity, among other parameters [14, 56, 
57]. Therefore, characterization of macroporous i-CPFs was conducted for 100-PITA 
samples. The i-CPFs displayed full conversion to calcium-deficient hydroxyapatite after 
setting, both with and without PITA (Supplementary Figure). As shown in the SEM 
images (Fig. 4), it was found that PITA did not induce observable changes in the 
microstructure of the set i-CPFs nor in the cohesion of the foamed pastes before setting. 
Similarly, MIP pore size entry distribution was found to be similar in both i-CPF and 
PITA loaded i-CPF (Fig. 6). SEM images showed plate like crystallites characteristic of 
the setting of α-TCP to calcium-deficient hydroxyapatite [58]. Also, reconstruction from 
the µCT scans allowed visualization of interconnected macropores.  The interconnected 
pores were seen clearly for control i-CPF as well as PITA (100 µM) loaded i-CPF. The 
skeletal density, total porosity and specific surface area were in accordance with previous 
results and displayed no significant differences among control i-CPF and PITA loaded i-
CPF at 100 µM. These findings were in agreement with other studies for statins, where 
they showed that SIM did not alter phase composition or porosity of cements [59]. 
It has been shown that 0.1 µM concentration can foster the expression of angiogenic 
and mineralization genes. Despite this, a much higher concentration of PITA was loaded 
in the i-CPFs. This was done with two considerations in mind: 1) the degradation of the 
drug due to the setting reaction (Table 2) that can be assumed to “inactivate” a ~6.5-8 % 
of the PITA incorporated in i-CPFs (as seen for 50, 75 and 100 µM) during the period of 
time in which the setting proceeds at basic pHs between 8 and 9.5; and 2) in our release 
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assays, having a detectable concentration of PITA had to be ensured (below 1 µM it was 
undetectable). Moreover, studying the release behavior of i-CPFs (Fig. 5) prepared at 
different concentrations may allow extrapolating it to adjust to the desired concentration 
in future. 
The initial burst release recorded was in agreement with other findings showing freshly 
prepared CPCs or pre-set CPCs set for short times which also display burst release [59]. The 
Korsmeyer-Peppas model was fitted to analyze the release kinetics (Table 4) but did not 
allow any conclusion as the parameter (n) was too low for the case of release from flat 
surfaces. On the other hand, some studies based on matrix tablets have shown that a value 
lower than n < 4.5 reflects a quasi-Fickian diffusion behavior [60, 61]. The profiles obtained 
can be ascribed to the evolving microstructure of the cement setting, which is responsible for 
the change in the elution regimes. Initially, the paste is just a suspension of α-TCP particles 
in aqueous solutions of PITA. As α-TCP precipitates to CDHA following the cement setting 
reaction, the network of CDHA crystals created progressively increases tortuosity, hindering 
the drug diffusion and reducing the release rate [59]. 
It has been observed that 50-PITA i-CPFs released 0.2 µg/mL which is very high in 
comparison to the 0.1 µM concentration shown to be effective in vitro. It is important to keep 
in account that release studies were designed with the aim of being within the detection range 
(1 µM) of HPLC technique for PITA. However, if we extrapolate the release values obtained 
at different concentrations we can estimate that a lower loading of PITA (5-10 µM) in i-
CPFs, will lead to a release around the 0.1 µM shown useful in vitro.   
When comparing the present findings with our previous work on simvastatin loaded 
scaffolds [62]: a) PITA shows a much higher loading efficiency due to its higher solubility 
than simvastatin, which gives an edge for incorporation of PITA through liquid phase b) 
Percentages released are much higher (~97 - 40 % PITA vs. 16 % Simvastatin), and 
progressive, which can be explained by the fact that i-CPFs are evolving matrices, with a 
high amount of liquid phase where PITA is dissolved, so in the initial release timeframe, 
exchange with the release media is much more favoured than with the set macroporous 
CDHA samples employed in previous works [62]. Moreover, PITA is efficient in vitro at 
lower dosages [63] so the progressive release behavior might allow to maximize the 
efficiency of the treatment. 
Different release profiles are reported in the literature for SIM with different calcium 
14  
phosphates: premixed cements [64] and CDHA cements and sintered ceramics [60, 62, 65]; 
However, it is the first time that PITA has been loaded within a calcium phosphate.   The i-
CPFs presented in this study exhibit a progressive release profile, corresponding to ~40% of 
the quantity loaded in 200-PITA and almost 97% released for 50-PITA and 75-PITA. The 
interconnected macroporosity (Fig. 6b) of all these samples is expected to enhance, in 
addition, tissue colonization. The release profile of all samples stabilized after 72 h wherein 
probably a significant amount of α-TCP had transformed already to CDHA, hindering the 
diffusion of the drug trapped within the crystal structure, as reflected in Fig. 6. 
Moreover, the macroporosity of the i-CPFs investigated can be assumed to foster higher 
amounts of drug released to the media, in comparison with their non-macroporous 





Pitavastatin was evaluated combined with i-CPFs as potential bone regeneration 
enhancer. First, PITA shows a stable behaviour in PBS at different working temperatures of 
37 ºC (important in i-CPFs preparation and in release studies) and of 5 ºC (relevant for its 
storage in solution), but a certain degradation (8%) was recorded in the setting conditions of 
the cements, so this should be taken into account when formulating the i-CPF dosage form. 
Second, i-CPFs and PITA loaded i-CPFs both exhibited similar interconnected macroporous 
structure with no significant changes in microstructure (Plate like crystallites), SSA, total 
porosity, pore size distribution or skeletal density. Third, 0.1 µM concentration of PITA 
resulted in the enhancement of gene expressions of OCN, collagen type 1 and BMP-2 in 
rMSCs indicating towards mineralization and differentiation. In the case of EPCs, gene 
expressions of VEGFA, VEGF-R2, and VEGF-R1 were enhanced by 72h as verified by RT- 
PCR indicative of angiogenesis. Finally, PITA loaded i-CPFs followed release kinetics 
according to the evolving microstructure of the foamed cement in the initial hours, with a 
burst release which slowly progressed to a slower release in a dose-dependent manner. 
Design of the i-CPFs as a drug delivery system loaded with PITA, an osteogenic and 
angiogenic promoter, allowing very low dosages, with the fact that it does not alter the 
attractive biomimetic features of the i-CPFs studied here makes them a captivating 
15  
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Figure and Table Captions 
 
 
Figure 1.  Chemical structure of the Pitavastatin used in this study. 
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Figure 2. Influence of temperature (5 and 37 ºC) (top) and pH (8 and 9.5) (37 ºC) on 
the stability of PITA solutions at different concentrations (Standard deviation was 






Figure 3. Influence of PITA on the gene expression of OCN, Col Type1, BMP-2 by 
rMSCs and VEGF-R1, VEGF-R2, VEGFA by EPCs and at 6, 24, 48 and 72 h.  The 
statistical difference with TCPS and 0.1 µM are represented as A and B respectively 













Figure 4. FESEM images of i-CPF of control and Pitavastatin loaded i-CPF with 100 







Figure 5. MIP pore size entry distribution (n=4) of i-CPF and PITA loaded i-CPF. 
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Figure 6. Total amount of PITA released at 72 h is plotted for each concentration of PITA 
loaded i-CPFs (a), and release curves of i-CPFs containing different amounts of PITA for 
6 days (b), with zoom of the initial 5 hours (c). Proposed scheme of the release of PITA  











Table 1: DNA sequences of forward (fw) and reverse (rv) primers for the selected genes 





Gene Title Primer sequences (5´-3´)  Acc. No. Amplico
n size 
(bp) 














































































Table 2: Degradation of PITA at pH 8 and pH 9.5 with the function of time (t = 24 h) and 
total degradation when loaded in i-CPFs 24 h, calculated according to eq. (2).  
 Degradation (%) (t = 24h) PITA degradation in i-CPFs 
setting reaction (%) (t = 
24h) 
 pH 8 pH 9.5 pH 9.5  pH 7 
5 μM 0 0 0 
25  μM 0 0 0 
50 μM 8.29 7.84 8.00 
75 μM 7.26 6.59 6.83 
100 μM 8.19 8.17 8.17 
 
 
Table 3: Specific surface area (SSA), skeletal density and Porosity of i-CPFs without 
and with PITA at 100 µM.  
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Total porosity (%) 
Control 7.89 2.34 74.39 ± 3.2 







Table 4: Percentage of total release of PITA in each i-CPF specimen after 72 h and values 
of R2 and n with Korsmeyer-Peppas model for the release kinetics. 
i-CPFs PITA released (%) Korsmeyer-Peppas (KP) 
n R2 
50-PITA 97.07 ± 10.95 0.29 0.9418 
75-PITA 97.02 ± 17.81 0.45 0.8813 
100-PITA 67.61 ± 13.51 0.32 0.8840 
200-PITA 40.93 ± 9.07 0.20 0.9097 
 
 
